Никотинзаместительная терапия в лечении табачной зависимости у пациентов с сердечно-сосудистыми заболеваниями

1. Lopez A. Smoking and death in Russia. Tobacco Control 1998; 7: 3–4.
2. World Health Organization – NCD Country Profiles, 2011. http://www.who.int/nmh/countries/rus_en.pdf
3. Wilhelmsen L. Coronary heart disease: epidemiology of smoking and intervention studies of smoking. Am Heart J 1988; 115: 242–9.
4. Шальнова С.А., Деев А.Д., Оганов Р.Г. Факторы, влияющие на смертность от сердечно-сосудистых заболеваний в российской популяции. Кардиоваск. терапия и профилактика. 2005; 4 (1): 4–9.
5. Rivers JT, White HD, Cross DB et al. Reinfarction after thrombolytic therapy for acute myocardial infarction followed by conservative management: Incidence and effect of smoking. J Am Coll Cardiol 1990; 16; 340–8.
6. Balfour D, Benowitz N, Fagerstrom K et al. Diagnosis and treatment of nicotine dependence with emphasis on nicotine replacement therapy. A status report. European Heart J 2000; 21: 438–45.
7. Iestra JA et al. A systematic review. Circulation 2005; 112: 924–34.
8. Международная классификация болезней МКБ-10. Класс: психические расстройства и расстройства поведения. Блок: психические расстройства и расстройства поведения, связанные с употреблением психоактивных веществ. http://www.mkb10.ru/?class=5&bloc=65
9. Региональное бюро ВОЗ. Глобальный опрос взрослого населения о потреблении табака. РФ, 2009.
10. Giovino GA, Henningfield JE, Tomar SL et al. Epidemiology of tobacco use and dependence. Epidem Rev 1995; 17: 48–65.
11. Hughes JR, Gulliver SB, Fenwick JW et al. Smoking cessation among self-quitters. Health Psychol 1992; 11: 331–4.
12. Rigotti NA, Singer DE, Mulley AG Jr, Thibault GE. Smoking cessation following admission to a coronary care unit. J Gen Intern Med 1991; 6: 305–11.
13. Jimenez-Ruiz CA, Masa F, Miravitlles M et al. Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest 2001; 119: 1365–70.
14. Walters N, Coleman T. Comparison of the smoking behaviour and attitudes of smokers who attribute respiratory symptoms to smoking with those who do not. Br J Gen Pract 2002; 52: 132–4.
15. Benowitz NL. Neurobiology of nicotine addiction: implications for smoking cessation treatment. Am J Med Vol 2008; 121 (4): 3–10.
16. Dani JA, De Biasi M. Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 2001; 70: 439–46.
17. Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci 2005; 8: 1445–9.
18. Benowitz NL. Nicotine addiction. Prim Care 1999; 26: 611–31.
19. Wang H, Sun X. Desensitized nicotinic receptors in brain. Brain Res Brain Res Rev 2005; 48: 420–37.
20. Dani JA, Heinemann S. Molecular and cellular aspects of nicotine abuse. Neuron 1996; 16: 905–8.
21. Brody AL, Mandelkern MA, London ED et al. Cigarette smoking saturates brain a4b2 nicotinic acetylcholine receptors. Arch Gen Psychiat 2006; 63: 907–15.
22. Hughes JR. Clinical significance of tobacco with drawal. Nicotine Tob Res 2006; 8: 153–6.
23. Tran K, Asakawa K, Cimon K et al. Pharmacologic-based strategies for smoking cessation: clinical and cost-effectiveness analyses. V. 2 (3). Cadth Technol Overv 2012; PMC 34426192010.
24. Henningfield JE. Nicotine medications for smoking cessation. N Engl J Med 1995; 333: 1196–203.
25. Treating tobacco use and dependence: 2008 update. Tobacco use and dependence guideline panel. Rockville (MD): US Department of Health and Human Services 2008.
26. Stead LF, Perera R, Bullen C et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2012; 14: 11. CD000146. doi: 10.1002/14651858. CD000146.pub4
27. Tonnesen R, Paoletti P, Gustavsson G et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Eur Resp J 1999; 13: 238–46.
28. Molyneux A, Lewis S, Leivers U et al. Clinical trial comparing nicotine replacement therapy (NRT) plus brief counselling, brief counselling alone, and minimal intervention on smoking cessation in hospital inpatients. Thorax 2003; 58 (6): 484–8.
29. Treating tobacco use and dependence: 2008 update. Tobacco use and dependence guideline panel. Rockville (MD): US Department of Health and Human Services 2008.
30. Mills EJ, Wu P, Lockhart I et al. Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals. Tobacco Induced Diseas 2010; 8 (8). http://www.tobaccoinduceddiseases.com/content/8/1/8
31. Ottervanger JP, Festen JM, Vries de AG, Stricker BH. Acute myocardial infarction while using the nicotine patch. Chest 1995; 107: 1765–6.
32. Ropchan GV, Sanfilippo AJ, Ford SE. Aortic dissection and use of the nicotine patch: a case involving a temporal relationship. Can J Cardiol 1997; 13: 525–8.
33. Van der Klauw MM, Van Hillo B, Van den Berg WH et al. Vasculitis attributed to the nicotine patch (Nicotinell). Br J Dermatol 1996; 134: 361–4.
34. Dacosta A, Guy JM, Tardy B et al. Myocardial infarction and nicotine patch: a contributing or causative factor? Eur Heart J 1993; 14: 1709–11.
35. Pierce JR Jr. Stroke following application of a nicotine patch [letter]. Ann Pharmacother 1994; 28: 402.
36. Warner JG Jr, Little WC. Myocardial infarction in a patient who smoked while wearing a nicotine patch [letter]. Ann Intern Med 1994; 120: 695.
37. Riche G, Nighoghossian N, Trouillas P. Intracerebral haematoma after application of nicotine patch [letter]. Lancet 1995; 346: 777–8.
38. Mathew TP, Herity NA. Acute myocardial infarction soon after nicotine replacement therapy [letter]. QJM 2001; 94: 503–4.
39. Ford CL, Zlabek JA. Nicotine replacement therapy and cardiovascular disease mayo. Clin Proc 2005; 80 (5): 652–6.
40. Working group for the study of transdermal nicotine in patients with coronary artery disease. Nicotine replacement therapy for patients with coronary artery disease. Arch Intern Med 1994; 154: 989–95.
41. Joseph AM, Norman SM, Ferry LH et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. 
N Engl J Med 1996; 335: 1792–8.
42. Greenland S, Satterfield MH, Lanes SF. A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch. Drug Saf 1998; 18: 297–308.
43. Kimmel SE, Berlin JA, Miles C et al. Risk of acute first myocardial infarction and use of nicotine patches in a general population. J Am Coll Cardiol 2001; 37: 1297–302.
44. Antman EM, Anbe DT, Armstrong PW et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction–executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 2004; 44: 671–719.

М.Г.Гамбарян

ФГБУ Государственный научно-исследовательский центр профилактической медицины Минздрава РФ, Москва